The Argentine government is debating proposals for the introduction of a Trade Secrets Act, which the national pharmaceutical industry association, Cilfa, fears could be detrimental to its interests.
Alberto Schilling, representing Cilfa and ALIFAR, the Latin American pharmaceutical industry organization (Marketletters passim), at an international conference on intellectual property in India (see pages 17, 24 and 25), told the Marketletter that Cilfa is concerned about a number of issues relating to the bill.
The organization fears that the bill may be an indirect way of implementing a pipeline clause and retroactivity in relation to intellectual property. Argentina introduced a new patent law in 1995 which does not contain these features (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze